Background and Rationale
Type 2 diabetes mellitus (T2DM) continues to be a major public health challenge globally, with a rapidly growing burden in China due to lifestyle changes and urbanization. Optimal glycemic control is critical to prevent complications associated with the disease. Basal insulin therapy is a commonly used treatment for patients with inadequate glycemic control on oral agents; however, intensification strategies remain a clinical need to enhance therapeutic effects without compromising safety.
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist, has shown promise in improving glycemic parameters and promoting weight loss in diverse populations. While evidence exists from global SURPASS trials, data specific to Chinese patients with T2DM treated with basal insulin were lacking. This prompted the SURPASS-CN-INS study to evaluate tirzepatide’s efficacy and safety when added to basal insulin within this population.
